Analyst firms · Morgan Stanley · GDRX
Morgan Stanley GDRX price target and rating history
GoodRx Holdings Inc. (GDRX) · Technology
Morgan Stanley rates GoodRx Holdings Inc. (GDRX) Equal-Weight with a $19 price target, as of its latest action on Mar 2, 2022. It has published 3 rating actions on GDRX since July 2021, including 0 upgrades and 0 downgrades.
- Current rating
- Equal-Weight
- Price target
- $19
- Median target, all firms
- Too few
- Actions on GDRX
- 3
Morgan Stanley price target on GDRX
Every Morgan Stanley rating on GDRX
- Mar 2, 2022
- Dec 17, 2021
- Jul 2, 2021
How other firms rate GDRX
Each firm's latest rating and stated target in the last 12 months.
Questions about Morgan Stanley and GDRX
- What is Morgan Stanley's price target for GDRX?
- Morgan Stanley's latest stated price target for GoodRx Holdings Inc. (GDRX) is $19, from its action on Mar 2, 2022.
- What is Morgan Stanley's rating on GDRX?
- Morgan Stanley rates GDRX Equal-Weight, a neutral rating, as of Mar 2, 2022.
- When did Morgan Stanley last change its view on GDRX?
- On Mar 2, 2022, Morgan Stanley cuts its price target to $19 from $41, keeps Equal-Weight.
More GDRX rating histories
- Barclays5
- Raymond James6
- RBC Capital Markets3
- J.P. Morgan3
- Leerink Partners4
- BofA Securities3
- TD Cowen3
- Goldman Sachs3
- Credit Suisse3
All Morgan Stanley ratingsGDRX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.